NanoViricides, Inc. (NYSE American: NNVC) has begun enrolling and dosing patients in a Phase II clinical trial evaluating its oral antiviral candidate, NV-387 Oral Gummies, as a treatment for Bundibugyo Ebolavirus and other Ebola viruses. The trial is taking place at an Ebola Treatment Center in the Ituri province of the Democratic Republic of Congo (DRC), a region that has experienced recurrent Ebola outbreaks. According to the announcement, the Phase IIA portion of the study started enrollment and dosing around September 23. This initial phase is designed to establish a safe and well-tolerated dosing protocol for NV-387. The resulting protocol will then be used in the Phase IIB portion, which will evaluate the drug's safety, tolerability, and effectiveness. The trial is registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077. For investors and industry observers, this development represents a significant milestone for NanoViricides, a clinical-stage company developing special purpose nanomaterials for antiviral therapy. Advancing a drug candidate into Phase II human trials is a critical and costly step that can substantially increase a company's value if successful. The fact that this trial is targeting Ebola—a highly lethal virus with limited treatment options—underscores the potential public health impact of a successful oral antiviral. Unlike some existing Ebola therapies that require intravenous administration, an oral gummy formulation could be easier to deploy in outbreak settings, particularly in remote areas where healthcare infrastructure is limited. The trial's location in the DRC is also notable because it allows for real-world evaluation against a virus that continues to pose a threat in parts of Africa. The company's lead drug candidate, NV-387, is being developed as a broad-spectrum antiviral with potential applications beyond Ebola, including RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox and measles. The company is also developing NV-HHV-1 for the treatment of shingles. NanoViricides' platform technology is based on the nanoviricide class of drug candidates, which are designed to attack viruses directly. The company holds a worldwide exclusive perpetual license to this technology for several drugs targeting specific human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Dengue, Japanese Encephalitis, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The company's business model relies on licensing technology from TheraCour Pharma, Inc. for specific application verticals. As with any drug development effort, there are substantial risks. The path to a commercial pharmaceutical product is lengthy and requires significant capital, and there can be no assurance that NV-387 will ultimately demonstrate sufficient effectiveness and safety for human clinical development. Nonetheless, the initiation of this Phase II trial provides valuable human data that could inform the future development of NV-387 across multiple indications. For more information about NanoViricides, visit its website at www.nanoviricides.com. The full press release can be viewed at https://ibn.fm/qC4Hk, and the latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC.
The announcement was distributed through MissionIR, a specialized communications platform that assists IR firms with syndicated content. MissionIR is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information about MissionIR, visit www.MissionIR.com, and the full terms of use and disclaimers are available at https://www.MissionIR.com/Disclaimer.
